# 1. Financial Performance ## A. Key Figures * Revenue: **₹1,388 Cr** Q3 FY26 (+22% YoY, +7% QoQ) * EBITDA: ₹308 Cr Q3 FY26 (+34% YoY) · ₹3,081 Mn (22.2% margin, +196 bps YoY) * **Gross Margin:** **63.9%** Q3 FY26 (+216 bps YoY, -183 bps QoQ) * ROCE: 16.8% Q3 FY26 (+60 bps QoQ) * **Net Working Capital:** **27% of sales** Q3 FY26 (from 33% at FY start) * Cash Flow from Operations: **₹21.87 Cr** Q3 FY26 * Net Debt: ₹10,151 million (~₹1,015 Cr) Q3 FY26 ## B. Revenue Growth * **Resilient Top-Line Expansion:** Strong double-digit revenue growth sustained despite temporary disruption in Peptide CDMO, with sequential improvement signaling recovery momentum. * **Execution Focus:** Q3 marked by intensive project activity and operational ramp-up, positioning for stronger Q4 delivery and reacceleration into FY27. ## C. EBITDA & Margins * **Margin Leverage Achieved:** EBITDA margin expanded significantly YoY and QoQ, driven by operating leverage and **favorable formulation mix**, even after absorbing **₹80 Cr EBITDA loss from Ascelis Peptides**. * **Core Profitability Strengthening:** Excluding Ascelis, underlying business shows clear improvement in both revenue and margins, with visibility into sustained gains from complex generics and remediation tail-off. * **Cost Pressures Transient:** High operating costs due to planned maintenance and customer-specific shifts were temporary, with benefits expected in Q4 output and margins. ## D. Cash Flow & Working Capital * **Working Capital Efficiency Improved:** Net working capital as % of sales declined sharply, and cash-to-cash cycle tightened slightly, reflecting better inventory and receivables management. * **Cash Flow Stability:** Operations generated stable cash flow despite rising working capital needs linked to sales growth, with positive operating cash flow trajectory expected to continue. ## E. Balance Sheet * **Capital Strength Enhanced:** Successful preferential issue completed with strong shareholder backing, boosting financial flexibility for strategic capex in CRMS and specialty formulations. * **Disciplined Capital Deployment:** Capex moderated in Q3, while net debt remained stable; proceeds to be deployed prudently with focus on value-accretive growth and balance sheet resilience. --- # 2. Product & Segment Performance ## A. Key Figures * **Complex Generics Revenue Mix:** **49%** of total (vs. 27% YoY, 40% QoQ) * **Ascelis Peptide Revenue:** **₹33 Cr** (up from ₹28–29 Cr in prior two quarters) * Peptide Franchise Loss: **₹25 Cr** (as stated in investor presentation, Q4 expected to reach EBITDA breakeven) ## B. Complex Generics Mix * **Strategic Pivot Accelerating:** Complex generics now represent nearly half of total revenue, reflecting successful shift toward higher-value, limited-competition products in CNS, ADHD, and oncology. * **Amphetamine Momentum:** Tentative approval for this strategically important ADHD product reinforces early-to-market positioning in controlled substances and validates complex generics pipeline. * **Operational Normalization Underway:** Gagillapur site recovery progressing, with commercial ramp-up expected this quarter as 1–2 Gpp products launch from Genome Valley. * **R&D Reorientation Confirmed:** Filing trends show increasing focus on complex generics, supported by advancements in TFA-free peptide chemistries enhancing differentiation in cosmetics and pharma. ## C. CDMO Business Trends * **CDMO Execution Gaining Traction:** Despite flat quarterly losses, project execution has strengthened since Q2, with key customer deliveries anticipated in Q4, signaling near-term revenue inflection. * **Platform Differentiation Expanding:** Ascelis Peptides and Senn Chemicals are building an integrated peptide CDMO platform with direct R&D contributions in India and growing innovator engagement. * **Commercial Pipeline Broadening:** Active feasibility discussions, sample seeding, and RFQ responses underway for amino acid derivatives and complex peptide fragments, targeting U.S. and global markets. --- # 3. Manufacturing & Capacity ## A. Site Remediation Progress * **Remediation on Track:** Gagillapur facility remediation remains on schedule, with a post-warning letter FDA meeting held in early January. * **Cost Trajectory Improving:** Remediation costs at Gagillapur have substantially declined and are expected to normalize over the next few quarters before becoming negligible. * **Temporary EBITDA Impact:** Ascelis Peptides’ quarterly EBITDA loss widened due to scheduled maintenance at the Senn Chemicals facility. ## B. Facility Utilization * **Capacity Expansion Underway:** Growth to be driven by increased production capacity and improved operational efficiencies, reversing prior underutilization trends. * **Scalable Footprint:** Gagillapur will have incremental capacity, while **GLS** will offer **significant headroom**; shared product lines across sites to enhance demand responsiveness. ## C. Automation & Digitalization * **Digital Transformation Accelerating:** Manual operations are being digitized network-wide, with GPI live, Gagillapur rollout complete by mid-calendar year, and further expansion planned. * **Next-Gen Plants Fully Automated:** New facilities, including the upcoming **Vizag API plant**, will be fully DCS-driven, paperless, and require minimal on-site personnel. * **R&D Integration:** Active collaboration between Swiss and Indian teams, anchored by the operational **Peptide Center of Excellence at IIT Hyderabad**. * **Quality & Competitiveness Focus:** Automation and digitization initiatives are enhancing regulatory compliance and sustaining cost competitiveness in API manufacturing. --- # 4. Regulatory & Compliance ## A. Key Figures * **FDA Inspection Observations:** **5** observations at Genome Valley (none data integrity) · **0** Form 483s at GCH U.S. packaging site * **Regulatory Approvals:** **1 tentative U.S. FDA approval** (Adzenys) · **1 EU**, **2 ROW**, and **1 China DMF approval** secured * **R&D Filings:** **1 EU DCP**, **8 ROW product registrations**, **4 ROW DMFs** filed ## B. FDA Inspection Outcomes * **Inspection Activity & Response:** GLS Genome Valley underwent unannounced PAS/GMP inspection; five observations received, all responded to on time, with no data integrity issues flagged. * **Post-Inspection Clearances:** PAS approval and EIR received for prior inspections; recent CBE-30 approval granted following latest FDA review. * **Agency Engagement:** Virtual FDA meeting in January yielded request for additional documentation, but **no concerns** raised on corrective action adequacy or pace. * **Product Approval Milestone:** Lisdexamfetamine chewable tablets and capsules approved by FDA, with GPI as approved entity; revenue timing not disclosed. ## C. International Certifications * **Global Quality Recognition:** Gagillapur facility awarded ANVISA Brazil GMP certification, reflecting strengthened quality systems. * **European Revenue Potential:** Pending European regulatory approval for Genome Valley expected to materially boost future revenue beyond initial launches. ## D. Filing & Approval Pipeline * **De-risking Strategy:** Select filings shifted to U.S. and GLS facilities; site transfers underway to ensure supply continuity and mitigate regulatory risk. * **Pipeline Momentum:** Upcoming launches supported by recent CBE-30 and PAS approvals, pending Gagillapur clearance. * **IP-Protected Opportunity:** Tentative FDA approval secured for generic Adzenys (amphetamine), an IP-protected product now in litigation phase. --- # 5. Demand & Customer Trends ## A. Key Figures * **Amphetamine Market Value:** **$220–230 Mn** annual ## B. Controlled Substances Demand * **Robust Market Expansion:** DEA’s significant quota increase reflects sustained and growing demand for lisdexamfetamine, validating market fundamentals and the company’s strategic positioning. * **Favorable Competitive Landscape:** Entry into a high-barrier market with only **one other generic competitor** enables meaningful revenue capture within complex generics. * **Sustained Commercial Traction:** Lisdexa products have delivered consistent, meaningful revenue over four quarters post-launch, despite late market entry. * **Paracetamol Recovery Underway:** Inventory overhang has eased in key markets, with rising demand for APIs, PFIs, and finished dosages driving regional growth amid persistent price pressure. ## C. Customer Engagement * **Share Gain Momentum:** Strong DEA compliance history has enabled favorable quota allocation and meaningful market share capture, with active plans to expand presence further. --- # 6. Risks & Regulatory Delays ## A. Regulatory Outlook – Gagillapur Facility * **FDA Engagement Ongoing:** Company expects formal feedback post-submission and remains confident in resolving outstanding issues, with a planned meeting scheduled for January 2026. * **Re-inspection Timeline Unclear:** Response to FDA will be submitted imminently, but agency-driven review process prevents any firm timeline for reinspection. ## B. Product Approval Delays * **Amphetamine Launch on Hold:** Launch timeline remains uncertain due to tentative approval status and active legal proceedings. * **Path to Final Approval:** If granted, final approval is expected to take **approximately one year** from tentative approval. --- # 7. Guidance & Outlook ## A. Key Figures * **B. S. Revenue Growth Run Rate:** **$40–50 Mn annually** added over past two years, expected to continue ## B. EBITDA Breakeven Target * **On Track for Q4 Breakeven:** Company reaffirms path to **EBITDA above breakeven** in the current quarter, driven by revenue scale-up and lower maintenance costs at Ascelis Peptides. * **Path to Sustained Profitability:** Targets **annual EBITDA neutrality starting FY27**, with expectation to remain in **positive territory** thereafter, despite inherent CDMO volatility. * **No Formal Guidance Provided:** Management reiterates no official financial guidance, though confirms outlook is positive. ## C. FY27 Growth Drivers * **Accelerating Momentum:** Capital raise enables growth acceleration, with **meaningful Q4 improvement** expected on delivery of matured projects. * **Margin & Sales Expansion:** Anticipates **sequential improvement in sales and margins** in FY27 via operational leverage, despite pending Gagillapur re-inspection.